Mabworks Biotech

We are a clinical-stage Chinese biopharmaceutical company focused on the discovery and development of innovative and differentiated antibody drugs, aiming to become a globally integrated biopharmaceutical company. Our mission is to translate scientific breakthroughs in immunology and cancer biology into novel antibody therapeutics, covering the biopharmaceutical market for oncology and autoimmune diseases, a rapidly growing market with unmet clinical needs both globally and in China. We will use this opportunity to continue to bring innovative and affordable treatment options to patients in these fields.

Based on our solid foundation in biomedical research, we have developed a range of featured antibody discovery and development technologies. According to the Frost & Sullivan report, our ADCC-enhanced antibody platform is one of the world's leading platforms for enhancing NK cell function through antibody glycosylation, and is currently the only self-developed and clinically proven platform with GMP manufacturing standards in China. similar platforms. Our multispecific antibody platform enables us to develop antibodies that bind to different targets simultaneously for synergistic therapeutic effects. Our antibody platform covers the entire process from antibody discovery to development, enabling us to design, evaluate, select and develop the best drug candidates in an efficient manner.

Using our proprietary antibody technology platform, we have developed a differentiated product pipeline consisting of 6 clinical-stage drug candidates and 6 representative preclinical drug candidates. Our core and main product MIL62 is China's first and only domestic third-generation CD20 antibody that has entered the phase III registration trial stage; MIL93 is a novel ADCC-enhanced Claudin 18.2 antibody with the potential to benefit a wider patient population; MBS301 is an ADCC-enhancing type HER2 bispecific antibody; MIL97 is a CD40 antibody with high agonist activity and good safety profile.

At the same time, our industry-leading antibody R&D capabilities have been recognized and validated through various strategic collaborations with leading biopharmaceutical companies in China. We have established cooperative relationships with biopharmaceutical companies such as Nuocheng Jianhua, Connoya, Betta Pharmaceuticals and Biositu at different stages of drug development. We expect this collaboration to generate important synergies with our internal research and development and to help us maximize the clinical and commercial value of our products.